TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL

Watchdoq January 6, 2025

(MedPage Today) -- A study presented at the American Society of Hematology annual meeting identified TCL1A as a potential predictive biomarker for blinatumomab (Blincyto) response in relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL...

Read Full Article